目的研究血管加压素1a受体(V1aR)拮抗剂对脑出血(in tracerebra l hem orrhage,ICH)后水孔蛋白-4(aquaporin-4,AQP 4)表达及血脑屏障(BBB)通透性的影响。方法运用立体定向技术,尾动脉采血制作大鼠脑出血模型。模型制作成功后,治疗组侧...目的研究血管加压素1a受体(V1aR)拮抗剂对脑出血(in tracerebra l hem orrhage,ICH)后水孔蛋白-4(aquaporin-4,AQP 4)表达及血脑屏障(BBB)通透性的影响。方法运用立体定向技术,尾动脉采血制作大鼠脑出血模型。模型制作成功后,治疗组侧脑室注射V1aR拮抗剂,对照组仅注射等量人工脑脊液。采用免疫组化技术对血肿周围组织AQP 4蛋白进行检测。通过检测渗出到脑血管外的伊文斯蓝(Evans B lue,EB)的含量来定量观察BBB的通透性。结果脑出血后6h尾壳核血肿周围组织AQP 4蛋白表达开始增高,在脑出血1d达高峰(P<0.01),持续到3d以后逐渐下降,到7d仍高于正常水平。而用V1aR拮抗剂脑室注射后,AQP 4蛋白表达在各时间点表达明显降低。BBB通透性在脑出血后6h开始升高,1d达高峰(P<0.01),3d后回落,侧脑室注入V1aR拮抗剂后,BBB通透性与对照组比较明显下降(P<0.05)。结论V1aR拮抗剂能抑制AQP 4蛋白的表达,保护BBB,减轻脑出血后脑水肿。展开更多
While the roles of glutamic acid （Glu）, arginine vasopressin （AVP） and their respective receptors in anxiety have been thoroughly investigated, the effects of interactions among Gila, N-methyl-D-aspartic acid （N...While the roles of glutamic acid （Glu）, arginine vasopressin （AVP） and their respective receptors in anxiety have been thoroughly investigated, the effects of interactions among Gila, N-methyl-D-aspartic acid （NMDA） receptor, AVP and a-amino-3- hydroxy-5-methylisoxazole-4-propionic acid （AMPA） receptor on anxiety are still unclear. In the present study, the agonist and antagonist of the NMDA receptor and AMPA receptor, as well as the antagonist of AVP V1 receptor （VlaR） were introduced into BALB/cJ mice by intracerebroventricular microinjection, and the anxiety-like behaviors of the mice were evaluated by open field and elevated plus-maze tests. Compared with C57BL/6 mice, BALB/cJ mice displayed higher levels of anxiety-like behavior. Significant anxiolytic effects were found in the NMDA receptor antagonist （MK-801） and the AMPA receptor or VlaR antagonist （SSRI49415）, as well as combinations of AVP/MK-801 and SSRI49415/DNQX. These results indicated that anxiety-like behaviors expressed in BALB/CJ mice may be due to a coordination disorder among glutamate, NMDA receptor, AMPA receptor, AVP and V1 aR, resulting in the up-regulation of the NMDA receptor and VlaR and down-regulation of the AMPA receptor. However, because the AMPA receptor can execute its anxiolytic function by suppressing AVP and VlaR, we cannot exclude the possibility of the NMDA receptor being activated by AVP acting on V1 aR.展开更多
文摘目的研究血管加压素1a受体(V1aR)拮抗剂对脑出血(in tracerebra l hem orrhage,ICH)后水孔蛋白-4(aquaporin-4,AQP 4)表达及血脑屏障(BBB)通透性的影响。方法运用立体定向技术,尾动脉采血制作大鼠脑出血模型。模型制作成功后,治疗组侧脑室注射V1aR拮抗剂,对照组仅注射等量人工脑脊液。采用免疫组化技术对血肿周围组织AQP 4蛋白进行检测。通过检测渗出到脑血管外的伊文斯蓝(Evans B lue,EB)的含量来定量观察BBB的通透性。结果脑出血后6h尾壳核血肿周围组织AQP 4蛋白表达开始增高,在脑出血1d达高峰(P<0.01),持续到3d以后逐渐下降,到7d仍高于正常水平。而用V1aR拮抗剂脑室注射后,AQP 4蛋白表达在各时间点表达明显降低。BBB通透性在脑出血后6h开始升高,1d达高峰(P<0.01),3d后回落,侧脑室注入V1aR拮抗剂后,BBB通透性与对照组比较明显下降(P<0.05)。结论V1aR拮抗剂能抑制AQP 4蛋白的表达,保护BBB,减轻脑出血后脑水肿。
基金This work was supported by the National Natural Science Foundation of China （31170377, 30970370） and the Fundamental Research Funds for Central University （GK201305009）
文摘While the roles of glutamic acid （Glu）, arginine vasopressin （AVP） and their respective receptors in anxiety have been thoroughly investigated, the effects of interactions among Gila, N-methyl-D-aspartic acid （NMDA） receptor, AVP and a-amino-3- hydroxy-5-methylisoxazole-4-propionic acid （AMPA） receptor on anxiety are still unclear. In the present study, the agonist and antagonist of the NMDA receptor and AMPA receptor, as well as the antagonist of AVP V1 receptor （VlaR） were introduced into BALB/cJ mice by intracerebroventricular microinjection, and the anxiety-like behaviors of the mice were evaluated by open field and elevated plus-maze tests. Compared with C57BL/6 mice, BALB/cJ mice displayed higher levels of anxiety-like behavior. Significant anxiolytic effects were found in the NMDA receptor antagonist （MK-801） and the AMPA receptor or VlaR antagonist （SSRI49415）, as well as combinations of AVP/MK-801 and SSRI49415/DNQX. These results indicated that anxiety-like behaviors expressed in BALB/CJ mice may be due to a coordination disorder among glutamate, NMDA receptor, AMPA receptor, AVP and V1 aR, resulting in the up-regulation of the NMDA receptor and VlaR and down-regulation of the AMPA receptor. However, because the AMPA receptor can execute its anxiolytic function by suppressing AVP and VlaR, we cannot exclude the possibility of the NMDA receptor being activated by AVP acting on V1 aR.
